VANCOUVER, British Columbia -- Treatment with higher-exposure dupilumab (Dupixent) led to sustained improvements in the reduction of peak esophageal intraepithelial eosinophil counts among children ...

Please provide your email address to receive an email when new articles are posted on . Revolo Biotherapeutics’ ‘1104 is designed to reset the immune system “upstream” before the inflammatory cascade ...

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

The phase 3 EoE KIDS study included 102 children with active eosinophilic esophagitis based on histologic improvement meeting validated histologic criteria. Positive results were announced from a ...

This article was originally published by HCPLive. Dupilumab may be a safe and effective treatment for pediatric patients with eosinophilic esophagitis (EoE), according to findings through week 52 of ...

Credit: Medical Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Allergens trigger the release of IL-18, which produces ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear. In a phase 3, ...

Sanofi and Regeneron Thursday announced positive results from a pivotal phase 3 trial of dupilumab (Dupixent) in children aged 1 to 11 years who have eosinophilic esophagitis (EoE). Dupilumab was ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

Over the next 5 years, investigators should focus on clarifying several important aspects of EGE that still remain unclear. First of all, clinical presentation, allergic diatheses association, and ...